The Economist7h
CRISPR cures face cost and safety concerns
Doctors harvest stem cells from the patient’s bone marrow and then send them off to a lab, where CRISPR is used to turn up the production of another, functional version of haemoglobin. This version is ...
STAT10h
An awkward moment for Pfizer’s Bourla in Washington
The future of the CDC’s vaccine advisory committee seems uncertain: A scheduled February meeting for the ACIP, which advises ...
CRISPR manipulation of UFO gene reveals complex plant flowering dynamics
Humans have appreciated the beauty of flowers for centuries. Yet, flowers aren't just aesthetically pleasing. They also play ...
CRISPR set to snap six days of gains as shares trade in red
Shares of CRISPR Therapeutics (NASDAQ:CRSP) were on track to snap six straight days of gains, as the stock fell more than 4% ...
Harvard Medical School1d
Creating the World’s First CRISPR Medicine, for Sickle Cell Disease
In December 2023, through the development efforts of CRISPR Therapeutics and Vertex Pharmaceuticals, their decades-long ...
CRISPR: From Discovery To Clinic—And Charting A Path Forward
No doubt 2025 will usher in many more advances in CRISPR therapies, thanks to the FDA’s new Platform Technology Designation ...
AcrVIB1: The unexpected anti-CRISPR protein that tightens RNA binding
The CRISPR-Cas gene scissors offer a wide range of potential applications, from the treatment of genetic diseases to ...
Q4 Earnings Surprise Greenlights CRISPR Therapeutics Stock Climb
CRISPR Therapeutics AG (CRSP) stock jumped over 9% this week after delivering strong Q4 2024 results ahead of schedule. The ...
Allworth Financial LP Purchases 14,398 Shares of CRISPR Therapeutics AG (NASDAQ:CRSP)
Allworth Financial LP lifted its position in shares of CRISPR Therapeutics AG (NASDAQ:CRSP – Free Report) by 2,117.4% during ...
NanoCas, a smaller version of CRISPR tested with a single AAV, delivers on-target results
Mammoth Biosciences researchers have developed NanoCas, an ultracompact CRISPR nuclease, demonstrating its ability to perform ...
Market Whales and Their Recent Bets on CRSP Options
In terms of liquidity and interest, the mean open interest for CRISPR Therapeutics options trades today is 628.14 with a total volume of 1,152.00.
The Economist7h
Gene editing has put biological research on a new trajectory
When the monkeys were single-celled embryos, scientists had used CRISPR editing tools to silence, or “knock out”, a gene that ...